5 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 51 points (0.4%) at 14,033 as of Tuesday, Feb. 19, 2013, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,948 issues advancing vs. 943 declining with 147 unchanged.

The Health Care sector currently sits up 2.7% versus the S&P 500, which is up 0.5%. Top gainers within the sector include Sanofi ( SNY), up 3.1%, Gilead ( GILD), up 1.8%, Merck ( MRK), up 1.2%, Pfizer ( PFE), up 0.9% and Novo Nordisk A/S ( NVO), up 0.7%. On the negative front, top decliners within the sector include Medtronic ( MDT), down 2.3%, Regeneron Pharmaceuticals ( REGN), down 2.2%, Aetna ( AET), down 1.7% and Cigna ( CI), down 1.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. GlaxoSmithKline ( GSK) is one of the companies pushing the Health Care sector higher today. As of noon trading, GlaxoSmithKline is up $0.27 (0.6%) to $45.89 on average volume Thus far, 1.1 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $45.70-$45.98 after having opened the day at $45.76 as compared to the previous trading day's close of $45.62.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $115.2 billion and is part of the drugs industry. The company has a P/E ratio of 13.7, below the S&P 500 P/E ratio of 17.7. Shares are up 4.9% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

These Stocks Pay You to Own Them

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Hikma Sinks on Advair Generic Concerns

Shire Gains as it Seeks European Approval For Dry Eye Treatment